Project description
AI for personalised medicine in pancreatic cancer
Pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. However, our understanding of its biology is improving rapidly and giving rise to innovative treatment strategies. The EU-funded PANCAIM project will apply existing genomic and clinical data to improve personalised medicine of pancreatic cancer. The innovative project integrates the entire range of genomics with radiomics and pathomics, which are the three pillars of future personalised medicine. PANCAIM applies a data-efficient two-staged AI method relying on four central concepts of AI in healthcare: data providers, clinical expertise, AI developers, and MedTech companies to connect to data and introduce AI into healthcare.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (9)
17177 Stockholm
See on map
0450 Oslo
See on map
28029 Madrid
See on map
G12 8QQ Glasgow
See on map
183 65 Taby
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
91052 Erlangen
See on map
3511 MJ Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
160 00 Praha 6
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
6525 XZ Nijmegen
See on map